Literature DB >> 11907122

Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells.

Nithiananthan Asokananthan1, Peter T Graham, Joshua Fink, Darryl A Knight, Anthony J Bakker, Andrew S McWilliam, Philip J Thompson, Geoffrey A Stewart.   

Abstract

Epithelia from many tissues express protease-activated receptors (PARs) that play a major role in several different physiological processes. In this study, we examined their capacity to modulate IL-6, IL-8, and PGE(2) production in both the A459 and BEAS-2B cell lines and primary human bronchial epithelial cells (HBECs). All three cell types expressed PAR-1, PAR-2, PAR-3, and PAR-4, as judged by RT-PCR and immunocytochemistry. Agonist peptides corresponding to the nascent N termini of PAR-1, PAR-2, and PAR-4 induced the release of cytokines from A549, BEAS-2B, and HBECs with a rank order of potency of PAR-2 > PAR-4 > PAR-1 at 400 microM. PAR-1, PAR-2, and PAR-4 also caused the release of PGE(2) from A549 and HBECs. The PAR-3 agonist peptide was inactive in all systems tested. PAR-1, PAR-2, or PAR-4, in combination, caused additive IL-6 release, but only the PAR-1 and PAR-2 combination resulted in an additive IL-8 response. PAR peptide-induced responses were accompanied by changes in intracellular calcium ion concentrations. However, Ca(2+) ion shutoff was approximately 2-fold slower with PAR-4 than with PAR-1 or PAR-2, suggesting differential G protein coupling. Combined, these data suggest an important role for PAR in the modulation of inflammation in the lung.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11907122     DOI: 10.4049/jimmunol.168.7.3577

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  112 in total

1.  Inhibition of interleukin-12 expression by alpha-thrombin in human peripheral blood mononuclear cells: a potential mechanism for modulating Th1/Th2 responses.

Authors:  A Naldini; L Aarden; A Pucci; C Bernini; F Carraro
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

Review 2.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

3.  Discovery of Novel Nonpeptidic PAR2 Ligands.

Authors:  Ilona Klösel; Maximilian F Schmidt; Jonas Kaindl; Harald Hübner; Dorothee Weikert; Peter Gmeiner
Journal:  ACS Med Chem Lett       Date:  2020-05-22       Impact factor: 4.345

Review 4.  Innate immune responses to environmental allergens.

Authors:  Henk F Kauffman
Journal:  Clin Rev Allergy Immunol       Date:  2006-04       Impact factor: 8.667

Review 5.  Structural biology of allergens.

Authors:  Wayne R Thomas; Belinda J Hales; Wendy-Anne Smith
Journal:  Curr Allergy Asthma Rep       Date:  2005-09       Impact factor: 4.806

Review 6.  Nasonasal reflexes, the nasal cycle, and sneeze.

Authors:  James N Baraniuk; Dennis Kim
Journal:  Curr Allergy Asthma Rep       Date:  2007-05       Impact factor: 4.806

Review 7.  New insights into protease-activated receptor 4 signaling pathways in the pathogenesis of inflammation and neuropathic pain: a literature review.

Authors:  Yanju Bao; Yebo Gao; Liping Yang; Xiangying Kong; Honggang Zheng; Wei Hou; Baojin Hua
Journal:  Channels (Austin)       Date:  2015       Impact factor: 2.581

8.  Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more.

Authors:  Martin O Judex; Barbara M Mueller
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

Review 9.  Gastrointestinal roles for proteinase-activated receptors in health and disease.

Authors:  A Kawabata; M Matsunami; F Sekiguchi
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

10.  Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents.

Authors:  Steeve Houle; Martin D Papez; Mara Ferazzini; Morley D Hollenberg; Nathalie Vergnolle
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.